| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5508144 | Biochimica et Biophysica Acta (BBA) - General Subjects | 2017 | 42 Pages |
Abstract
Chelerythrine is still marketed as a specific PKC inhibitor and extensively used in signal transduction studies. We believe that the described off-target effects should preclude its use as a PKC inhibitor in future works.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Ana Saavedra, Sara Fernández-GarcÃa, Silvia Cases, Mar PuigdellÃvol, Rafael Alcalá-Vida, Núria MartÃn-Flores, Jordi Alberch, Silvia Ginés, Cristina Malagelada, Esther Pérez-Navarro,